肝脏神经内分泌肿瘤的临床特点及治疗
Clinical Characteristics and Treatment of Hepatic Neurorndorine Neoplasms
DOI: 10.12677/ACM.2021.1111797, PDF,   
作者: 董玉纯, 包永星*:新疆医科大学第一附属医院,新疆 乌鲁木齐
关键词: 肝脏神经内分泌肿瘤Liver Neurorndorine Neoplasms
摘要: 神经内分泌肿瘤(neurorndorine neoplasms, NENs)指的是那些来源于神经内分泌系统的肿瘤。NENs在临床上比较少见,故原发的肝脏神经内分泌肿瘤更少见。NENs易发生肝转移,临床上见到的肝脏神经内分泌肿瘤往往为转移性的肝脏神经内分泌肿瘤,其临床症状和影像学检查结果都没有明显的特异性,因此必须结合多方面的检查手段,排除肝外原发可能。基于目前这种情况,原发或继发肝脏的NENs的鉴别及诊断是一个复杂的过程,单纯的病理结果并不能完全明确原发疾病。结合目前的情况,有必要对肝脏NENs的临床特征、诊断以及治疗进行系统的梳理。
Abstract: Neurorndorine neoplasms (NENs) are a kind of tumor derived from neuroendocrine system. NENs are relatively rare in clinic, so primary neuroendocrine neoplasms of the liver are rarer. NENs are prone to liver metastasis. The hepatic neuroendocrine neoplasms seen clinically are often metastatic hepatic neuroendocrine neoplasms, and their clinical symptoms and imaging findings have no obvious specificity, so it is necessary to combine various examination methods to exclude the existence of extrahepatic primary lesions in order to diagnose. Based on the current situation, the differentiation and diagnosis of primary or secondary liver NENs are a complex process, simple pathological results cannot completely identify the primary disease. Therefore, this article reviews the clinical features, diagnosis, differential diagnosis and treatment of hepatic neuroendocrine neoplasms.
文章引用:董玉纯, 包永星. 肝脏神经内分泌肿瘤的临床特点及治疗[J]. 临床医学进展, 2021, 11(11): 5391-5397. https://doi.org/10.12677/ACM.2021.1111797

参考文献

[1] Bosman, F.T., Carneiro, F., Hruban, R.H., et al. (2010) WHO Classilication of Tumours of the Digestive System. 4th Edition, International Agency for Research on Cancer Press, Lyon, 196-250.
[2] Elmugtaba, I.M., Kerolos, A., Zhai, Q.J., et al. (2017) Primary Hepatic Neuroendocrine Tumor with Unusual Thyroid Follicular-Like Morphologic Characteristics. Case Reports in Pathology, 2017, Article ID: 7931975.
[Google Scholar] [CrossRef] [PubMed]
[3] Quartey, B. (2011) Primary Hepatic Neuroendocrine Tumor: What Do We Know Now? World Journal of Oncology, 2, 209-216.
[Google Scholar] [CrossRef] [PubMed]
[4] 杨秋霞, 吴静, 张嵘. 神经内分泌肿瘤的诊断研究进展[J]. 国际医学放射学杂志, 2011, 34(5): 418-421.
[5] Trofimiuk-Müldner, M., Lewkowicz, E., Wysocka, K., et al. (2017) Epidemiology of Gastroenteropancreatic Neuroendocrine Neoplasms in Krakow and Krakow District in 2007-2011. Endokrynologia Polska, 68, 42-46.
[Google Scholar] [CrossRef
[6] Dasari, A., Shen, C., Halperin, D., et al. (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncology, 3, 1335-1342.
[Google Scholar] [CrossRef] [PubMed]
[7] De Luzio, M., Barbieri, A., Israel, G., et al. (2017) Two Cases of Primary Hepatic Neuroendocrine Tumors and a Review of the Current Literature. Annals of Hepatology, 16, 621-629.
[Google Scholar] [CrossRef] [PubMed]
[8] Andreola, S., Lombardi, L., Audisio, R.A., et al. (1990) A Clinicopathologic Study of Primary Hepatic Carcinoid Tumors. Cancer, 65, 1211-1218.
[Google Scholar] [CrossRef
[9] Sioutos, N., Virta, S. and Kessimian, N. (1991) Primary Hepatic Carcinoid Tumor. Anelectron Microscopic and Immunohistochemical Study. American Journal of Clinical Pathology, 95, 172-175.
[Google Scholar] [CrossRef] [PubMed]
[10] Gravante, G., De Liguori, C.Ni., Overton, J., et al. (2008) Primary Carcinoids of the Liver: A Review of Symptoms, Diagnosis and Treatments. Digestive Surgery, 25, 364-368.
[Google Scholar] [CrossRef] [PubMed]
[11] Gupta, S. (2013) Intra-Arterial Liver-Directed Therapies for Neuroendocrine Hepatic Metastases. Seminars in Interventional Radiology, 30, 28-38.
[Google Scholar] [CrossRef] [PubMed]
[12] Yao, J.C., Hassan, M., Phan, A., et al. (2008) One Hundred Years after “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. Journal of Clinical Oncology, 26, 3063-3072.
[Google Scholar] [CrossRef
[13] Modlin Irvin, M., Oberg, K., Chung, D.C., et al. (2008) Gastroenteropancreatic Neuroendocrine Tumours. Lancet Oncology, 9, 61-72.
[Google Scholar] [CrossRef
[14] Beaumont, J.L., Cella, D., Phan, A.T., et al. (2012) Comparison of Health-Related Quality of Life in Patients with Neuroendocrine Tumors with Quality of Life in the General US Population. Pancreas, 41, 461-466.
[Google Scholar] [CrossRef
[15] Shetty, P.K., Baliga, S.V., Balaiah, K., et al. (2010) Primary Hepatic Neuroendocrine Tumor: An Unusual Cystic Presentation. Indian Journal of Pathology and Microbiology, 53, 760-762.
[Google Scholar] [CrossRef] [PubMed]
[16] Tohyama, T., Matsui, K. and Kitagawa, K. (2005) Primary Hepatic Carcinoid Tumor with Carcinoid Syndrome and Carcinoid Heart Disease: A Case Report of a Patient on Long-Term Follow-up. Internal Medicine, 44, 958-962.
[Google Scholar] [CrossRef] [PubMed]
[17] Chen, Q., Zhao, H., Zhao, J., Bi, X., Li, Z., Huang, Z., Zhang, Y., Zhou, J. and Cai, J. (2018) Clinical Features and Prognostic Factors of Cryptogenic Hepatocellular Carcinoma. Translational Cancer Research, 7, 729-737.
[Google Scholar] [CrossRef
[18] Chen, Z., Xiao, H.-E., Ramchandra, P., et al. (2014) Imaging and Pathological Features of Primary Hepatic Neuroendocrine Carcinoma: An Analysis of Nine Cases and Review of the Literature. Oncology Letters, 7, 956-962.
[Google Scholar] [CrossRef] [PubMed]
[19] Hope, T.A., Bergsland, E.K., Bozkurt, M.F., et al. (2018) Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. Journal of Nuclear Medicine, 59, 66-74.
[Google Scholar] [CrossRef] [PubMed]
[20] Ronot, M., Clift, A.K., Baum, R.P., et al. (2018) Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver Metastases. Neuroendocrinology, 106, 74-88.
[Google Scholar] [CrossRef] [PubMed]
[21] Miki, M., Ito, T., Hijioka, M., et al. (2017) Utility of Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors. Japanese Journal of Clinical Oncology, 47, 520-528.
[Google Scholar] [CrossRef] [PubMed]
[22] Arnold, R., Wilke, A., Rinke, A., et al. (2008) Plasma Chromogranin A as Marker for Survival in Patients with Metastatic Endocrine Gastroenteropancreatic Tumors. Clinical Gastroenterology and Hepatology, 6, 820-827.
[Google Scholar] [CrossRef] [PubMed]
[23] Jensen, E.H., Kvols, L., McLoughlin, J.M., et al. (2007) Biomarkers Predict Outcomes Following Cytoreductive Surgery for Hepatic Metastases from Functional Carcinoid Tumors. Annals of Surgical Oncology, 14, 780-785.
[Google Scholar] [CrossRef] [PubMed]
[24] Foster, J.H. and Berman, M.M. (1977) Solid Liver Tumors. Major Problems in Clinical Surgery, 22, 1-342.
[25] Foster, J.H. and Lundy, J. (1981) Liver Metastases. Current Problems in Surgery, 18, 157-202.
[Google Scholar] [CrossRef
[26] Pavel, M., O’Toole, D., Costa, F., et al. (2016) ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology, 103, 172-185.
[Google Scholar] [CrossRef] [PubMed]
[27] Farley Heather, A. and Pommier Rodney, F. (2016) Treatment of Neuroendocrine Liver Metastases. Surgical Oncology Clinics of North America, 25, 217-225.
[Google Scholar] [CrossRef] [PubMed]
[28] Cannon, R., Ellis, S., Hayes, D., et al. (2013) Safety and Early Efficacy of Irreversible Electroporation for Hepatic Tumors in Proximity to Vital Structures. Journal of Surgical Oncology, 107, 544-549.
[Google Scholar] [CrossRef] [PubMed]
[29] Mayo, S.C., de Jong, M.C., Bloomston, M., Pulitano, C., Clary, B.M., Reddy, S.K., et al. (2011) Surgery Versus Intra-Arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis. Annals of Surgical Oncology, 18, 3657-3665.
[Google Scholar] [CrossRef] [PubMed]
[30] Shen, C., Shih, Y.-C.T., Xu, Y., et al. (2015) Octreotide Long-Acting Repeatable among Elderly Patients with Neuroendocrine Tumors: A Survival Analysis of SEER-Medicare Data. Cancer Epidemiology, Biomarkers & Prevention, 24, 1656-1665.
[Google Scholar] [CrossRef
[31] Clift, A.K. and Frilling, A. (2014) Management of Patients with Hepatic Metastases from Neuroendocrine Tumors. Annals of Saudi Medicine, 34, 279-290.
[Google Scholar] [CrossRef] [PubMed]
[32] Raymond, E., Dahan, L., Raoul, J.-L., et al. (2011) Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 364, 501-513.
[Google Scholar] [CrossRef
[33] Maroon, J., Kocha, W., Kvols, L., et al. (2006) Guidelines for the Diagnosis and Management of Carcinoid Tumours. Part 1: The Gaetrointestinal Tract. A Statement from a Canadian National Carcinoid Expert Group. Current Oncology, 13, 67-76.
[Google Scholar] [CrossRef] [PubMed]
[34] Öberg, K., Knigge, U., Kwekkeboom, D., et al. (2012) Neuroendocrine Gastro-Entero-Pancreatic Tumors: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 23, vii124-vii130.
[Google Scholar] [CrossRef] [PubMed]
[35] Fazio, N., Granberg, D., Grossman, A., et al. (2013) Everolimus plus Octreotide Long-Acting Repeatable in Patients with Advanced Lung Neuroendocrine Tumors: Analysis of the Phase 3, Randomized, Placebo-Controlled RADIANT-2 study. Chest, 143, 955-962.
[Google Scholar] [CrossRef] [PubMed]
[36] Pavel, M.E., Becerra, C., Grosch, K., et al. (2017) Effect of Everolimus on the Pharmacokinetics of Octreotide long-Acting Repeatable in Patients with Advanced Neuroendocrine Tumors: An Analysis of the Randomized Phase III RADIANT-2 Trial. Clinical Pharmacology & Therapeutics, 101, 462-468.
[Google Scholar] [CrossRef] [PubMed]
[37] Ott Patrick, A., Bang, Y.-J., Piha-Paul, S.A., et al. (2019) T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated with Pembrolizumab Across 20 Cancers: KEYNOTE-028. Journal of Clinical Oncology, 37, 318-327.
[Google Scholar] [CrossRef
[38] Fan, Y., Ma, K., Wang, C., et al. (2016) Prognostic Value of PD-L1 and PD-1 Expression in Pulmonary Neuroendocrine Tumors. OncoTargets and Therapy, 9, 6075-6082.
[Google Scholar] [CrossRef